Vertex Pharmaceuticals (VRTX) Insider Trading & Ownership $443.05 +1.53 (+0.35%) As of 01:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Vertex Pharmaceuticals (NASDAQ:VRTX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage0.20%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)12Amount OfInsider Selling(Last 12 Months)$34.04 M Get VRTX Insider Trade Alerts Want to know when executives and insiders are buying or selling Vertex Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address VRTX Insider Buying and Selling by Quarter Vertex Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails11/15/2024David AltshulerEVPSell15$478.56$7,178.40 8/30/2024Jeffrey M LeidenChairmanSell3,784$499.00$1,888,216.00 8/30/2024Sangeeta N BhatiaDirectorSell646$500.00$323,000.00 8/7/2024Carmen BozicCMOSell2,280$476.75$1,086,990.00 8/1/2024Bruce I SachsDirectorSell5,295$508.00$2,689,860.00 7/24/2024Carmen BozicCMOSell2,280$488.46$1,113,688.80 7/22/2024Reshma KewalramaniCEOSell15,202$497.00$7,555,394.00 7/10/2024Carmen BozicCMOSell2,280$487.34$1,111,135.20 6/26/2024Carmen BozicCMOSell2,280$471.72$1,075,521.60 6/12/2024Carmen BozicCMOSell2,280$478.00$1,089,840.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 6/12/2024Edward Morrow Atkinson IIIEVPSell7,288$478.00$3,483,664.00 5/30/2024Ourania TatsisEVPSell2,350$439.11$1,031,908.50 5/29/2024Carmen BozicCMOSell2,280$445.56$1,015,876.80 5/28/2024Charles F Wagner JrCFOSell3,250$454.79$1,478,067.50 5/24/2024Reshma KewalramaniCEOSell1,565$457.00$715,205.00 5/22/2024Bruce I SachsDirectorSell7,073$448.00$3,168,704.00 5/3/2024Tommy TubervilleU.S. Congress Member (R-AL)Sell$401.08$1,001 - $15,0002/26/2024Ourania TatsisEVPSell354$425.70$150,697.80 2/20/2024Ourania TatsisEVPSell480$420.79$201,979.20 2/12/2024Amit SachdevEVPSell3,222$420.24$1,354,013.28 2/12/2024Jeffrey M LeidenChairmanSell2,656$419.51$1,114,218.56 2/12/2024Kristen AmbroseCAOSell1,374$420.24$577,409.76 2/12/2024Stuart A ArbuckleCOOSell4,295$420.24$1,804,930.80 (Data available from 1/1/2013 forward) VRTX Insider Trading Activity - Frequently Asked Questions Who is on Vertex Pharmaceuticals's Insider Roster? The list of insiders at Vertex Pharmaceuticals includes Amit Sachdev, Bastiano Sanna, Bruce I Sachs, Carmen Bozic, Charles F Wagner Jr, David Altshuler, Edward Morrow Atkinson III, Jeffrey M Leiden, Jonathan Biller, Joy Liu, Kristen Ambrose, Lloyd Carney, Margaret G Mcglynn, Ourania Tatsis, Reshma Kewalramani, Sangeeta N Bhatia, Stuart A Arbuckle, and Yuchun Lee. Learn more on insiders at VRTX. What percentage of Vertex Pharmaceuticals stock is owned by insiders? 0.20% of Vertex Pharmaceuticals stock is owned by insiders. Learn more on VRTX's insider holdings. Which Vertex Pharmaceuticals insiders have been selling company stock? The following insiders have sold VRTX shares in the last 24 months: Amit Sachdev ($1,354,013.28), Bastiano Sanna ($5,176,395.04), Bruce I Sachs ($21,162,600.50), Carmen Bozic ($14,548,270.35), Charles F Wagner Jr ($3,998,815.80), David Altshuler ($427,969.53), Edward Morrow Atkinson III ($3,483,664.00), Jeffrey M Leiden ($13,592,878.66), Jonathan Biller ($211,523.60), Kristen Ambrose ($1,019,800.59), Lloyd Carney ($865,404.00), Ourania Tatsis ($2,456,075.67), Reshma Kewalramani ($12,174,267.36), Sangeeta N Bhatia ($786,860.82), and Stuart A Arbuckle ($8,449,055.39). How much insider selling is happening at Vertex Pharmaceuticals? Insiders have sold a total of 234,009 Vertex Pharmaceuticals shares in the last 24 months for a total of $89,707,594.59 sold. Which members of congress are trading Vertex Pharmaceuticals? Tommy Tuberville (R-AL) has sold shares of Vertex Pharmaceuticals in the last year totaling $8,000. Vertex Pharmaceuticals Key ExecutivesDr. Jeffrey Marc Leiden M.D. (Age 68)Ph.D., Executive Chairman Compensation: $95.02kDr. Reshma Kewalramani FASN (Age 51)M.D., CEO, President & Director Compensation: $5.59MMr. Charles F. Wagner Jr. (Age 56)Executive VP & CFO Compensation: $2.12MMr. Stuart A. Arbuckle B.Sc. (Age 58)Executive VP & COO Compensation: $2.76MDr. David M. Altshuler M.D. (Age 59)Ph.D., Executive VP & Chief Scientific Officer Compensation: $2.17MMs. Kristen C. Ambrose CPA (Age 47)Senior VP & Chief Accounting Officer Mr. Mike TirozziSVP and Chief Information & Data OfficerSusie LisaSenior Vice President of Investor RelationsMr. Jonathan Biller J.D. (Age 60)Executive VP & Chief Legal Officer Ms. Nina DevlinSenior VP & Chief Communications Officer More Insider Trading Tools from MarketBeat Related Companies Amgen Insider Selling Gilead Sciences Insider Selling Regeneron Pharmaceuticals Insider Selling Alnylam Pharmaceuticals Insider Selling Biogen Insider Selling United Therapeutics Insider Selling Neurocrine Biosciences Insider Selling Incyte Insider Selling BioMarin Pharmaceutical Insider Selling Exact Sciences Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insider Selling in Tech Stocks Spikes in Q43 Small-Cap Stocks Insiders and Institutions Are Buying3 Stocks With Strong Capital Returns and Insider Buying SignalsZymeworks in Focus for Insider Activity: Catalysts AheadInsiders Are Loading Up: 3 Key Stock Picks for Investors This page (NASDAQ:VRTX) was last updated on 1/30/2025 by MarketBeat.com Staff From Our PartnersWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredTrump’s New AI Move Could Trigger Massive Melt UPIn his first week in office, President Trump already revoked President Biden's disastrous AI executive order.....InvestorPlace | SponsoredTrillion-Dollar Crypto PlayPotential $20-trillion opportunity? Put $500 into THIS AI Coin for 2025… Crypto 101 Media | SponsoredIs Big Tech dead?China just threw a “$5.5 million” curveball called Deep Seek to Silicon Valley and the timing of it is no coin...Brownstone Research | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredDonald Trump is about to free crypto from its chains …On October 25th, Juan said Bitcoin would cross $100,000 before the inauguration. Now he thinks it could rea...Weiss Ratings | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vertex Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Vertex Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
